NCT04762641View on ClinicalTrials.gov

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

June 15, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

ABL503

ABL503 will be administered intravenously (IV) on Day 1 and Day 15 of every 28-day cycle in the dose-escalation part. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.

Trial Locations (8)

78229

RECRUITING

NEXT Oncology, San Antonio

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

90033

RECRUITING

USC, Los Angeles

90404

RECRUITING

UCLA, Santa Monica

91010

RECRUITING

City of Hope, Duarte

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

ABL Bio, Inc.
All Listed Sponsors
lead

ABL Bio, Inc.

INDUSTRY